ClinicalTrials.gg
CompletedNCT01253083Updated Dec 17, 2019

Mobility Training to Improve Motor Behavior in Toddlers With or at Risk for Cerebral Palsy: A Pilot Study

A Phase 1 interventional study of mobility training with dynamic body weight support in Developmental Delay and Cerebral Palsy, sponsored by National Institutes of Health Clinical Center (CC). Completed at 1 site in United States. Open to participants aged 12 Months to 36 Months. Per ClinicalTrials.gov, last updated 2019-12-17.

Sponsored by National Institutes of Health Clinical Center (CC) · Phase 1, Interventional, and Treatment

Phase
Phase 1
Study type
Interventional
Enrollment
5
Allocation
Non-randomized
Ages
12 Months to 36 Months
Sex
All
01

Study summary

Background:

- People who have cerebral palsy often have difficulty walking and moving their legs. Cerebral palsy is sometimes not identified until a child is almost 2 years of age, which means that early motor skill development can be affected and can have repercussions for later development. Studies in adults with neurological injuries (e.g., stroke, spinal cord injury) have shown that it is important to start intensive therapy soon after the injury, and it may be true that starting intensive therapy at a young age will be helpful for children with cerebral palsy. Researchers are interested in testing the effectiveness of a special body weight support system for mobility training in young children who have or are at risk for cerebral palsy.

Objectives:

- To study the effectiveness of a mobility training program on the motor skills of young children who have or are at risk for cerebral palsy.

Eligibility:

- Children between 12 and 36 months of age who have delayed motor skills and either have been diagnosed with cerebral palsy or show evidence of spasticity or brain damage.

Design:

  • This study involves two 6-week study phases: a baseline phase and a mobility training program.
  • Participants will be screened with a physical examination and medical history.
  • During the baseline phase, participants will have mobility testing sessions once every 2 weeks. These tests will measure motor development and ability, including ease and speed of walking.
  • Participants' parents/guardians will receive a mobility sensor for the child to wear at home for at least 6 hours (awake time) to measure activity and mobility levels outside of the testing sessions.
  • After 6 weeks of baseline testing, participants will have 6 weeks of mobility training for 30 minutes 3 days per week. Training will involve motor tasks with weight support, conducted by a pediatric physical therapist. Activities may include walking, climbing inclines or steps, or squatting to reach toys. All sessions will be videotaped.
  • To evaluate the effects of the therapy program, participants will have testing sessions every 2 weeks.
  • Parents/guardians will also complete questionnaires to provide feedback on the effectiveness of the therapy program.
Read the detailed description

The purpose of this pilot study is to test the feasibility and effects of a functional mobility training program on the motor ability and physical activity of young children who are developmentally delayed and at risk for cerebral palsy (CP). The study includes a sample of 10 participants between 12-36 months of age who have at least a 4 month motor delay and are at risk for CP in a single-subject research design with repeated measures during baseline and intervention phases. Participants will have biweekly assessments during the 6 week baseline phase and the subsequent 6 week mobility training phase, followed by a final assessment after 6 weeks of treatment withdraw. Assessments and training will occur in the Functional and Applied Biomechanics (FAB) section. The mobility training program consists of three days per week of 30 minute treatment sessions using dynamic body weight support during a variety of functional motor tasks. Children will be assisted, but not limited, by the dynamic weight support system while they are encouraged to participate in a variety of age-appropriate mobility tasks. It is hypothesized that this system combined with the functional activity practice will facilitate the development of postural control and strength, and thereby improve walking ability. The primary outcome measures are completion rate and gross motor ability as measured by the Gross Motor Function Measure (GMFM). Secondary outcome measures include the amount of gross motor delay as measured by the Bayley Motor Scale (BMS),, the Functional Mobility Scale (FMS), spatiotemporal gait measures, and amount of physical activity in daily life. Results of this pilot study will be used to refine the mobility training program, evaluate the appropriateness of the selected outcome measures, and to provide preliminary data for a larger scale clinical trial.

02

Conditions studied

  • Developmental Delay
  • Cerebral Palsy

Keywords

  • Mobility
  • Developmental Delay
  • Cerebral Palsy
  • Early Walking
  • Postural Control
03

In context

Learning Disabilities

150 studies on the registry are indexed under Learning Disabilities; 51 are open to participants now.

This study's enrollment of 5 is below the median of 60 across 101 interventional studies indexed under Learning Disabilities.

Browse Learning Disabilities studies →

Lead sponsor

National Institutes of Health Clinical Center (CC) is the lead sponsor of 375 studies on the registry; 27 are open to participants now.

Of its 23 completed or terminated interventional studies of FDA-regulated products, 19 (83%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
12 Months to 36 Months
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. 12-36 months of age

    1. greater than or equal to 4 months of gross motor delay corrected for gestational age (measured by Bayley Motor Scale)
    2. Diagnosis of bilateral spastic cerebral palsy OR neurological evidence of spasticity or brain damage
    3. Ability to pull to stand at a surface without assistance
    4. Cognitive ability to follow one-step commands
    5. Availability to return to NIH CC with parent or caregiver for required treatment and assessment sessions

Exclusion criteria

EXCLUSION CRITERIA:

  1. Unilateral cerebral palsy
  2. Secondary orthopedic, neuromuscular or cardiovascular condition unrelated to CP
  3. Greater than six months of independent walking experience
  4. History of surgery or injury to the lower extremities in the past 6 months
05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
5 participants (actual)

Interventions

  • Behavioralmobility training with dynamic body weight support
06

What researchers measure

Primary outcomes

  1. Change in motor delay

Secondary outcomes

  1. Completion rate, change in gross motor function, change in functional mobility, change in walking speed, change in physical activity

07

Study locations

1 site
  • National Institutes of Health Clinical Center, 9000 Rockville Pike
    Bethesda, Maryland 20892, United States
08

References and documents

Publications

  • Rosenbaum P, Paneth N, Leviton A, Goldstein M, Bax M, Damiano D, Dan B, Jacobsson B. A report: the definition and classification of cerebral palsy April 2006. Dev Med Child Neurol Suppl. 2007 Feb;109:8-14. PubMed 17370477 ↗
  • Yeargin-Allsopp M, Van Naarden Braun K, Doernberg NS, Benedict RE, Kirby RS, Durkin MS. Prevalence of cerebral palsy in 8-year-old children in three areas of the United States in 2002: a multisite collaboration. Pediatrics. 2008 Mar;121(3):547-54. doi: 10.1542/peds.2007-1270. PubMed 18310204 ↗
  • Odding E, Roebroeck ME, Stam HJ. The epidemiology of cerebral palsy: incidence, impairments and risk factors. Disabil Rehabil. 2006 Feb 28;28(4):183-91. doi: 10.1080/09638280500158422. PubMed 16467053 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2010, a primary completion of Jun 2014 and a completion of Jun 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 2, 2010
First posted
Dec 3, 2010
Start
Nov 15, 2010
Primary completionActual
Jun 6, 2014
CompletionActual
Jun 6, 2014
Last update
Dec 17, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 17, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01253083
Responsible party
Sponsor
First posted
Dec 3, 2010
Start date
Nov 15, 2010
Primary completion
Jun 6, 2014
Completion
Jun 6, 2014
Last update
Dec 17, 2019

Study contacts

Diane L Damiano, Ph.D.
principal investigator · National Institutes of Health Clinical Center (CC)
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion